{"id":192581,"name":"BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.","slug":"boehringer-ingelheim-pharmaceuticals-inc","state":"CT","country":"United States of America","description":"pharmaceutical company","totalSpending":1790000,"filings":34,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":200000},{"year":2020,"income":200000},{"year":2021,"income":200000},{"year":2022,"income":250000},{"year":2023,"income":200000},{"year":2024,"income":340000},{"year":2025,"income":200000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"FOR","display":"Foreign Relations"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["THORN RUN PARTNERS"],"lobbyists":["ANDREW ROSENBERG","GARY PALMQUIST","CHARLES THOMAS","BEAU SCHUYLER","PAUL BOCK","HARRIET MELVIN"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Cost Sharing (Preserving Access to Medicines). Healthcare Exchanges. Average Sales Price. Reimbursements. Children's Health Insurance Program (CHIP). Brand safety and security.","Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign ","Rebates for dual eligible and low-income subsidy population in Medicare Part D. Non-Interference. Implementation of the 21st Century Cures Act (P.L.114-255). ADUFA Reauthorization.\nPart D coverage gap","Value Based Contracting.\nBrand safety and security.","Legislation related to CFIUS and FARA including issues related to critical technologies and export controls;\nS.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017;\nS.2482, Foreign "]}